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A  reduction of unnecessary healthcare such as the overutilization of services,  the overuse of medi-
cations,  and overtreatment is a global challenge.  The 
overuse of medicine may result not only in disease or 
disorders but also in a higher volume of healthcare pro-
vided,  at a higher cost than is appropriate [1 , 2].  A 
reduction in overused tests and treatments is thus rec-
ommended [3].
Japan is a ‘super-aging’ society,  as is rapidly becom-
ing the case in many nations,  and information gained 
about unnecessary healthcare in Japan will be useful 
worldwide.  Polypharmacy,  a type of unnecessary 
healthcare that is considered a risk factor for complica-
tions among elderly people [4-6],  is defined as taking 6 
or more drugs [7].  The number of elderly people (espe-
cially those aged ≥ 75 years) who have many chronic 
diseases has increased and consequently,  so has the 
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chance of these adults receiving fragmented and over-
lapping medical services from multiple medical institu-
tions [8].
Based on an analysis of the data of hospitalized 
patients at acute care hospitals in Japan (2,412 records,  
mean age: 78.1 years),  older patients taking 6 or more 
drugs had a higher risk of adverse drug reactions [9].  
Another study showed that geriatric outpatients taking 
five or more drugs were at a high risk of falls [10].  Only 
a few reports have described a population-representa-
tive prevalence or the number of patients with poly-
pharmacy in Japan,  and these studies had small sample 
sizes and were limited to patients in specific medical 
institutions [9 , 10].
Japan has provided universal healthcare coverage for 
over half a century,  across several types of health insur-
ance systems [11].  Under the Japanese system,  health 
insurance claim (HIC) data have recently been used for 
the identification of healthcare profiles,  including 
patient counts and treatment status,  in large popula-
tions [12].  The health insurance system in Japan is 
broadly classified into three public systems: the National 
Health Insurance (NHI),  Employees’ Health Insurance 
(EHI),  and Late-stage Elderly Health Insurance (LEHI) 
[11].  The NHI is generally operated at the municipal 
level and covers self-employed workers as well as unem-
ployed and retired individuals.  The EHI covers salaried 
workers in companies and factories and their depen-
dents.  The NHI and EHI cover all eligible individuals 
aged < 75 years,  and the LEHI covers all individuals 
aged ≥ 75 years,  regardless of their employment status.
For the LEHI,  the administrative entity is the union 
of the late-stage elderly residents’ medical care system 
established in each of Japan’s 47 prefectures,  to which all 
municipalities join.  Medical facilities issue claims for 
the reimbursement of costs of healthcare services in a 
given calendar month,  excluding monthly copayments,  
according to the patients’ health insurance package.  The 
NHI organizations,  which are located in the same pre-
fecture as the medical facilities,  investigate HICs to 
determine (1) the patient’s qualification status and (2) if 
the healthcare services provided meet the regulations of 
the reimbursement rules [13].
We were thus able to conduct analyses if the entire 
population of elderly people living in a specific region 
by using the HICs in the NHI and LEHI systems.  The 
data that we analyzed covered an entire prefecture whose 
population is over 1 million (Nagasaki Prefecture).  Our 
present analyses differed from those of previous studies,  
which were limited to data from specific medical insti-
tutions [9 , 10].
Although there have been investigations of health 
insurance claims data,  most of the investigations used 
data from the NHI [14],  EHI [15],  or the Diagnosis 
Procedure Combination data [16] for analysis.  There 
have been few studies using LEHI data.  We conducted 
the present study to determine the prevalence of poly-
pharmacy among elderly people in a Japanese prefecture 
by using a large-scale population-based HIC database’s 
data.
Materials and Methods
Study design and data source. This study was 
conducted in Nagasaki Prefecture,  and the study popu-
lation comprised all of the beneficiaries of the NHI and 
LEHI in Nagasaki Prefecture.  The prefecture is the 
southernmost of the 4 main islands of Japan,  where 
1.34 million people resided in a 4,093-km2 region.  As of 
April 2016,  the prefecture had a total number of 
1,395,120 residents,  and the numbers of NHI and LEHI 
beneficiaries were 393,137 and 212,269,  respectively.
This was a population-based retrospective descrip-
tive study using HIC information.  We included all of the 
NHI and LEHI outpatient and pharmaceutical HIC data 
for the prefecture from April to June 2016.  Under a 
research agreement with the Federation of Health 
Insurance Organizations in Nagasaki Prefecture,  infor-
mation that could identify individuals such as names,  
the identification number of the insured person,  and 
dates of birth was anonymized,  and we created new 
identification codes to sum up the information of the 
HICs by using the hash function.
When individual beneficiaries moved from the NHI 
to the LEHI,  the Federation of Health Insurance 
Organizations in Nagasaki Prefecture connected the 
information of the individual’s qualification status for 
both the NHI and LEHI in order to create the new 
identification codes.  We were thus able to establish a 
system that did not contain any information that could 
identify the personal information of the beneficiaries.  
The data obtained included the patients’ age and sex,  
information on the number of drugs prescribed,  and 
information on the pharmacy fee and pharmaceutical 
fee scores.  We identified persons who received drug 
prescriptions among all insured person,  and we nar-
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rowed down the analysis to persons with polypharmacy,  
i.e.,  using 6 or more drugs in a single month.
This study was carried out in accordance with the 
Declaration of Helsinki and was approved by the ethics 
committee of Teikyo University (approval no. 17-032) 
and Kurume University (approval no. 18140).
Definition of polypharmacy. In Japan,  prescrip-
tions are commonly obtained at a hospital or clinic,  and 
medicines are then dispensed at pharmacies outside the 
medical facilities.  These are referred to as out-of-hospi-
tal prescriptions.  In some cases,  medicines are obtained 
at pharmacies inside a hospital or clinic.  These are 
referred to as in-hospital prescriptions.
From April to June 2016,  by using the HIC data of 
both in- and out-of-hospital prescriptions,  we summed 
all of the prescribed drugs including both internal and 
external medicines issued to each insured person for 
each calendar month.  We then summed the number of 
prescribed medicines from April to June to calculate the 
average number of prescribed drugs for each insured 
person.  During the study period,  polypharmacy was 
defined as taking 6 or more drugs per month,  based on 
a previous study and the guidelines of the Japan 
Geriatrics Society [7 , 8].
Based on the average number of drugs prescribed,  
an average monthly number of six or more drugs was 
regarded as polypharmacy status.  The average monthly 
number of drugs is presented for the following reasons:  
(1) A study on long-term (> 2 months) drug prescrip-
tions is also being conducted in Japan; (2) we com-
bined the outside and in-hospital prescriptions; and (3) 
even if duplicate drugs were prescribed by different 
medical facilities,  each drug could be counted.
Persons with prescriptions and insured persons.  
‘Persons with prescriptions’ were defined as those pre-
scribed one or more drugs during the follow-up period.  
‘Insured persons’ were defined as NHI or LEHI benefi-
ciaries in Nagasaki Prefecture,  regardless of whether or 
not they were prescribed any drugs.
Statistical analysis. We calculated the character-
istics of the insured persons prescribed drugs,  includ-
ing their age,  the number of drugs used,  the pharmacy 
fee (Japanese yen),  and the pharmaceutical fee 
(Japanese yen) (110 yen=1 US dollar as of June 20,  2018) 
according to the patient’s polypharmacy status.  A chi-
square test and t-test were used for categorical and con-
tinuous variables,  respectively,  based on differences in 
polypharmacy status.  We calculated the numbers and 
percentages of persons in the different age groups 
among those aged ≥ 65 years with polypharmacy,  by 
sex.  P-values < 0.05 were considered statistically signif-
icant.
All statistical analyses were performed using EZR 
(ver. 1.36; Saitama Medical Center,  Jichi Medical 
University,  Saitama,  Japan),  a graphical user interface 
for R (The R Foundation for Statistical Computing,  
Vienna,  Austria).  More precisely,  EZR is a modified 
version of R commander,  designed to add the statistical 
functions frequently used in biostatistics [17].
Results
The number of individuals prescribed one or more 
drugs at least once during the study period was 379,988 
(225,668 in the NHI and 154,320 in the LEHI),  
accounting for 62.8% of all NHI and LEHI beneficiaries 
as of April 2016.  For those aged ≥ 65 years,  78.1% of 
the residents in Nagasaki Prefecture were prescribed 
one or more drugs at least once during the study period.  
The age distributions of the insured persons (n=605,406) 
and the persons with prescriptions (n = 379,988) are 
shown in Table 1.
Table 2 summarizes the characteristics of the per-
sons with prescriptions according to their polyphar-
macy status.  The mean age of the persons with pre-
scriptions was 70.3 years,  and 41.8% of these persons 
were male.  The median number of drugs prescribed 
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????? ?　 Age distributions of the persons with insurance and 
those with prescriptions
Persons with 
prescriptions
Persons with 
insurance
Participation rate by age group
0-9 years (%,  n) 2.7 (10,429) 3.3 (19,819)
10-19 years (%,  n) 2.2 (8,385) 4.1 (24,745)
20-29 years (%,  n) 1.9 (7,120) 4.0 (24,186)
30-39 years (%,  n) 2.6 (9,940) 5.1 (30,577)
40-49 years (%,  n) 3.6 (13,760) 6.4 (38,533)
50-59 years (%,  n) 5.5 (20,961) 8.5 (51,181)
60-69 years (%,  n) 21.2 (80,401) 23.3 (141,026)
70-79 years (%,  n) 29.2 (110,978) 22.8 (138,184)
80-89 years (%,  n) 24.5 (92,952) 18.0 (108,832)
≥90 years (%,  n) 6.6 (25,062) 4.7 (28,323)
Total 100 (379,988) 100 (605,406)
Male sex (%) 41.8 45.5
Data are the mean±standard deviation (SD),  percentage and num-
ber,  or median and interquartile range,  as appropriate.
was 3.7 per patient,  ranging from 1.7 to 7.0.  The phar-
macy and pharmaceutical fees,  per patient,  were 6,600  
yen and 25,590 yen,  respectively.  Overall,  121,033 
(31.9%) persons had polypharmacy status.  The persons 
with polypharmacy were significantly more likely to be 
female (p < 0.001),  older (p< 0.001),  with a higher phar-
macy fee (p < 0.001) and a higher pharmaceutical fee 
score (p < 0.001).
Table 3 indicates the numbers of patients in the dif-
ferent age groups among those aged ≥ 65 years with 
polypharmacy,  by sex.  In total,  121,033 persons 
engaged in polypharmacy (45,629 males and 75,404 
females),  of which 110,538 with polypharmacy were 
aged ≥ 65 years.
Table 4 provides the percentages of persons with 
prescriptions and insured persons with polypharmacy,  
by age and sex.  Among the persons with prescriptions,  
the percentage of those with polypharmacy increased 
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????? ?　 Characteristics of persons with prescriptions according to polypharmacy status
Persons with prescriptions
Polypharmacy
(－)
(N＝258,955)
(＋)
(N＝121,033)
p-value
Age (years） 70.3 (19.3) 65.8 (20.6) 79.2 (12.4) ＜0.001
Male sex (%) 41.8 43.5 37.7 ＜0.001
Number of drugs 3.7 (1.7-7.0) 2.5 (1.6) 10.2 (3.9) ＜0.001
Pharmacy fee (yen) 6,600 (2,100-13,500) 1,100 (380-2,250) 5,600 (4,250-7,500) ＜0.001
Pharmaceutical fee (yen) 25,570 (6,370-72,240) 3,920 (1,120-10,600) 31,000 (17,660-54,410) ＜0.001
Data are the mean±SD,  percentage and number,  or median and interquartile range,  as appropriate.
????? ?　 Classiﬁcation of persons with polypharmacy aged ≥65 years according to age group and sex
Number of persons with polypharmacy
Age Total Males Females
65-69 years 9,760 4,810 4,950
70-74 years 14,272 6,414 7,858
75-79 years 23,298 9,139 14,159
80-84 years 26,901 9,973 16,928
85-89 years 21,661 6,838 14,823
≥90 years 14,646 3,387 11,259
Total number of persons aged ≥65 years 110,538 40,561 69,977
Total number of persons 121,033 45,629 75,404
????? ?　 Percentage of persons with polypharmacy aged ≥65 years according to age group and sex
Persons with prescriptions Persons with insurance
Age Total Males Females Total Males Females
65-69 years (%) 17.8 19.0 16.9 11.1 11.5 10.8
70-74 years (%) 28.5 28.8 28.3 22.2 22.4 22.0
75-79 years (%) 38.3 36.2 39.7 31.6 29.6 33.0
80-84 years (%) 49.2 46.1 51.2 41.4 39.7 42.4
85-89 years (%) 56.6 53.1 58.4 49.4 48.8 49.8
≥90 years (%) 58.5 64.6 59.1 51.7 62.8 50.9
% of total persons aged ≥65 years 39.0 35.8 31.5 30.5 27.7 32.3
% of total persons 31.8 28.8 34.0 20.0 16.9 22.4
Data are expressed as percentages.
with age,  with 31.8% engaged in polypharmacy overall 
(28.8% males and 34.0% females).  In particular,  about 
40% of those aged ≥ 65 years engaged in polypharmacy.  
Among the insured persons,  similar results were 
obtained,  with 20.0% engaged in polypharmacy,  30.5% 
of whom were aged ≥ 65 years.
In summary,  approximately one-third of the persons 
with prescriptions engaged in polypharmacy,  with 
approximately one-fifth of insured persons engaged in 
polypharmacy.  Among those aged ≥ 65 years,  the poly-
pharmacy rate was high at 39% of the persons with 
prescriptions and 30% of the insured.  Among those 
aged > 85 years,  about half engaged in polypharmacy.
Discussion
Our analyses clarified the prevalence of polyphar-
macy among the beneficiaries of the NHI and LEHI in 
Nagasaki Prefecture,  Japan.  About one-fifth of the ben-
eficiaries of the NHI and LEHI engaged in polyphar-
macy,  and this was especially prevalent among those 
aged > 85 years,  half of whom engaged in polyphar-
macy.
There are several reasons for this large number of 
elderly people engaging in polypharmacy.  In Japan,  
most older patients tend to receive fragmented and 
overlapping medical services from multiple medical 
institutions [8].  The medical records of patients are 
usually created per facility,  with no opportunity to con-
firm the existence of a patient’s medical records from 
one facility to the other.  A similar situation has been 
recognized with pharmacies.  The pharmaceutical dis-
pensing history in one pharmacy in Japan cannot be 
confirmed in another pharmacy.  To improve this situa-
tion,  the use of only one “family pharmacy” has been 
recommended with which the entire history of an indi-
vidual from both the medical institution(s) and phar-
macies can be accurately and continuously monitored 
for each individual.  Pharmaceutical management,  
guidance,  and medication histories can also be moni-
tored accurately with the use of the single family phar-
macy,  and all historical records can then be consoli-
dated [18].
However,  only 20% of patients were familiar with 
the concept of a family pharmacy [19].  Considering 
this,  many patients used 2 or more pharmacies,  thereby 
making it difficult to ascertain how many drugs each 
patient has taken.  As a result,  the numbers of drugs 
taken by patients are likely to increase [20].  Family 
physicians also play an important role in solving this 
issue [7].  It is the responsibility not only of the family 
pharmacy but also the family physician to determine 
how many drugs each patient takes.  The family physi-
cian must also manage patients’ prescriptions while 
considering the health care goals and activity level of 
each patient.
Few studies have discussed the polypharmacy status 
in a population-representative situation.  In a study of 
660 patients who visited one of the geriatric outpatient 
units of five university hospitals,  the average number of 
drugs taken was 4.4 [8].  Another observational study 
indicated that among patients hospitalized for geriatric 
internal medical care,  the average numbers of drugs 
taken for cases without and with adverse events during 
hospitalization were 5.0 ± 3.6 and 5.7 ± 4.1,  respectively 
[21].  However,  since the prior studies of polypharmacy 
were limited to patients in specific medical institutions,  
the polypharmacy status in a population-representative 
situation has not been established.  Our present findings 
revealed this status by using the HICs data of about 
370,000 individuals who were prescribed drugs and the 
data of beneficiaries without prescribed drugs during 
the study period.
The average number of drugs prescribed in our 
study population was 3.7,  and about half of the patients 
aged > 80 years were using 6 or more drugs.  In another 
study,  the higher average number of drugs reported was 
not consistent with our present results.  We suspect that 
the previous results were obtained because the target 
population was comprised of individuals from geriatric 
outpatient units and thus may not represent the total 
population.  The strengths of our present investigation 
lie in the characteristics of the study population,  which 
included all patients aged ≥ 75 years within the prefec-
ture as well as patients who did not receive prescrip-
tions during the follow-up.  Thus,  our results showing 
that the state of polypharmacy in this population-rep-
resentative situation was much higher than expected,  
especially among elderly people,  may be generalized.
In elderly people,  adverse drug events — which tend 
to occur frequently — may be associated with polyphar-
macy due to their aging and to a reduction in kidney 
and/or liver functions.  In Japan,  > 10% of hospitalized 
patients are reported to experience adverse drug events 
[8].  It has been reported that 88% of hospital admis-
sions due to adverse drug events in elderly people,  are 
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preventable,  and that the number of cases can be sev-
enfold higher in older than in younger individuals [22].  
According to Fried et al.  [23],  it is important to care-
fully consider the benefits and risks involved in drug 
selection strategies as well as strategies to reduce the 
drug intakes of elderly people.  The Screening Tool Of 
Older Person’s Prescriptions and the Screening Tool To 
Alert Doctors to the Right Treatment criteria as well as 
the Beers Criteria have been proposed in Europe and 
the United States,  and they have been used in the selec-
tion of drugs for elderly people [24 , 25].
In 2015,  the Japan Gerontological Society announced 
the ‘Guidelines for Medical Treatment and Its Safety in 
Elderly People 2015,’ which recommended that pre-
scriptions for individuals aged ≥ 75 years and those aged 
< 75 years with frailty or under nursing care be reviewed 
[7].  Because the risk-benefit trade-offs of managing 
medications in older patients is a complicated problem,  
the use of these guidelines is said to be of benefit [26].  
In our present study,  drugs that should not be adminis-
tered based on these guidelines were not investigated.  
Considering the high prevalence of polypharmacy 
among elderly people,  future studies should investigate 
the association between polypharmacy and prognoses.
Notably,  this study has three major strengths.  The 
first is that it included data from multiple family and 
hospital pharmacies.  In Japan,  the pharmaceutical dis-
pensing history in one pharmacy cannot be confirmed 
by another pharmacy.  We therefore used HIC data in 
this study,  which means that even if patients used mul-
tiple pharmacies,  it was possible to include all of the 
information about their prescribed drugs under their 
health insurance package.  The second major strength of 
this study was that,  by using HIC data,  even if there 
was a change from the NHI to LEHI insurance cover-
age,  the transfer of patient information from one 
agency to another is possible.  A study using the 
Diagnosis Procedure Combination data [16] could not 
detect the situation in which the subject changed insur-
ance coverage within the analyzed period.  Under the 
current system,  generally,  patients are supposed to 
automatically begin to participate in the LEHI on their 
75th birthdays,  but even if the patients withdraw from 
the NHI and move to LEHI,  their data (e.g.,  personal 
information) are not connected.  Since we used HIC 
data and the qualification status information from both 
the NHI and the LEHI,  even if any patient changed 
insurance coverage within the analyzed period,  there 
was no data loss.
The third major strength of this study was our eval-
uation of the patients’ data covering 3 consecutive 
months,  including cases with long-term prescriptions.  
In Japan,  the average interval since the last outpatient 
visit has increased [27].  Moreover,  the limitation of the 
lengths of drug prescriptions was cancelled in 2002,  
with exceptions for some special medications.  According 
to a questionnaire conducted by the Japan Medical 
Association,  the average interval since the last outpa-
tient visit among patients with chronic diseases such as 
hypertension and dyslipidemia was ≥ 8 weeks for 
approximately half of the patients <Japan Medical 
Association,  URL: http://www.med.or.jp/etc/eq201103/
hoken/110311eq140.pdf>.  In our study,  we evaluated 
an interval of 3 consecutive months,  and it was thus 
possible to evaluate all data (even the long-term [> 8-
week] prescriptions).
There are also several limitations to our study,  most 
of which are related to the use of HIC data.  First,  we 
did not directly investigate the specific prescription sit-
uations; we only obtained the available HIC informa-
tion.  Since there was no information regarding over-
the-counter drugs not covered by the health insurance 
system,  our results could have underestimated the 
number of drugs used by older patients.  However,  
under the Japanese universal healthcare insurance 
system,  it is possible to obtain all of the information 
about drugs covered by the health insurance system 
from the HIC data.  There is a need for further studies 
that include over-the-counter drugs not covered by the 
health insurance.
Secondly,  it is possible that this study underesti-
mated the number of drugs prescribed per month.  
Even if the period between visits was the same,  there 
might have been 2 patterns: (1) the first visit was before 
April and the second visit was between April and June,  
and (2) both the first and second visits were between 
April and June.  It is also possible that the number of 
drugs prescribed per month may have varied during the 
study period,  even though the interval between patient 
visits was the same.  The actual number of drugs pre-
scribed per month may have been greater than the value 
obtained in this study.  However,  this does not affect the 
interpretation of the results substantially.  Future studies 
should investigate the mean daily number of medica-
tions taken by patients determine more precisely the 
actual polypharmacy status.
?? ???????????? ????????? ????????????? ???? ???? ??
Thirdly,  we did not have information on the types or 
amounts of drugs prescribed and did not analyze the 
differences between regularly prescribed drugs and 
temporary drugs.  Further analyses considering this 
difference between regularly prescribed drugs and med-
icines to be taken as needed are desirable.  Fourth,  our 
study population was limited to beneficiaries of the NHI 
and LEHI.  However,  we investigated all of the people 
aged ≥ 75 years in Nagasaki Prefecture because the LEHI 
covers all of the residents aged ≥ 75 years within the 
prefecture.  Fifth,  we could not confirm whether the 
patients’ prescriptions were appropriate.  All drugs have 
potential benefits as well as risks,  and the trade-off 
between the benefits and risks is difficult to quantify.  
Similarly,  a relationship between polypharmacy and 
under-prescription has been reported; the probability 
of under-prescription increased significantly with the 
number of medicines being used [28 , 29].  Under-
prescription may be an important aspect of inappropri-
ate prescribing for individuals with polypharmacy.  
Under-prescription can also put a patient at risk for 
disease,  such as cardiovascular diseases [30].  Future 
studies should investigate both the prevalence of non- 
recommended drug use/under-prescription based on 
the relevant guidelines and the association between 
polypharmacy and the risk of adverse drug reactions as 
well as health outcomes by using large-scale popula-
tion-based data.
Lastly,  a distinguishing feature of Nagasaki 
Prefecture is the number of islands included in the pre-
fecture.  One of the prefecture that has the largest num-
ber of islands with inhabitants in Japan,  Nagasaki 
Prefecture is comprised of approximately 73 islands.  
While the population of residents of the islands is 
approximately 10% of the total Nagasaki population,  
most people who live on the islands are older,  and 
because of limited medical facilities on the islands,  
medical care is often limited.  Consequently,  these 
elderly residents are more likely be prescribed multiple 
medications per medical visit.  This potential for over-
prescribing may have affected our results [31].
In conclusion,  we used the HIC data from a large-
scale population-based database to investigate the num-
ber of elderly patients with polypharmacy.  Our analyses 
demonstrated that about one-third of the elderly people 
had polypharmacy status,  and about half of the people 
aged > 85 years had polypharmacy status.  These results 
showed that the number of elderly people with poly-
pharmacy in population-representative settings might 
be much higher than previously described.
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